Screening breast cancer patients for Norwegian ATM mutations

British Journal of Cancer

Volumn 83, Issue 12, 2000, Pages 1650-1653

  Laake, K ^a   Vu, P ^a   Andersen, T I ^b   Erikstein, B ^a   Karesen R ^b   Lonning, P E ^c   Skovlund, E ^a   Borresen Dale, A L ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Ataxia telangiectasia; Breast cancer risk; Breast neoplasms; Heterozygote detection; Norwegian founder mutation; Polymerase chain reaction

Indexed keywords

ATM PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; ATAXIA TELANGIECTASIA; BREAST CANCER; CANCER RISK; CANCER SCREENING; FEMALE; GENE MUTATION; HETEROZYGOSITY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MUTATION RATE; NORWAY; PRIORITY JOURNAL;

ALLELES; BREAST NEOPLASMS; CELL CYCLE PROTEINS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MASS SCREENING; NORWAY; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 0034541440     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1519     Document Type: Article

References (32)

1. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
2. Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility
3. Absence of mutations in the ATM gene in breast cancer patients with severe responses to radiotherapy
4. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer
5. Absence of mutations in the ATM gene in forty-seven cases of sporadic breast cancer
6. A-T-tributable risk?
7. Ataxia-telangiectasia: An overview
8. ATM heterozygous germline mutations contribute to breast cancer susceptibility
9. Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas
10. The role of ataxia-telangiectasia heterozygotes in familial breast cancer
11. Cancer risks in A-T heterozygotes
12. Heterozygous ATM mutations do not contribute to early onset of breast cancer
13. Cancer risk in ATM heterozygotes: A model of phenotypic and mechanistic differences between missense and truncating mutations
14. Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia
15. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer
16. Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: Haplotype study in French AT families
17. Loss of heterozygosity at 11q231 in breast carcinomas: Indication for involvement of a gene distal and close to ATM
18. Identical mutation in 55% of the ATM alleles in 11 Norwegian AT families: Evidence for a founder effect
19. Characterisation of ATM mutations in 41 Nordic families with ataxia telangiectasia
20. An allelic variant at the ATM locus is implicated in breast cancer susceptibility
21. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease
22. Cancer in patients with ataxia-telangiectasia and their relatives - A collaborative study of the Nordic countries
23. Sequence analysis of the ATM gene in 20 patients with RTOG grade 3 or 4 acute and/or late tissue radiation side effects
24. Heterozygous germline ATM mutation do not contribute to radiation-associated malignancies after Hodgkin's disease
25. Ataxia-telangiectasia - A primary immunodeficiency revisited
26. A single ataxia telangiectasia gene with a product similar to kinase to Pl-3
27. Ataxia-telangiectasia
28. Heterozygosity for mutations in the ataxia telangiectasia gene is not a major cause of radiotherapy complications in breast cancer patients
29. Incidence of cancer in 161 families affected by ataxia-telangiectasia
30. A haplotype common to intermediate radiosensitivity variants of ataxia-telangiectasia in the UK
31. ATM mutations in cancer families
32. The ATM gene and susceptibility to breast cancer: Analysis of 38 breast tumors reveals no evidence for mutation